TrialOncology research and treatment2026

Safety and Preliminary Activity of Neoadjuvant Trastuzumab Deruxtecan plus 5-Fluorouracil and Folinic Acid for HER2-Positive, Resectable Esophagogastric Adenocarcinoma: Results from the Safety Run-In Cohort of the Phase Ib/II UCCL-AIO-STO0124-IKF072 NeoART Trial.

Gertraud Stocker et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.